Gain new insights with CTCs — discover the AdnaTest LungCancer and ProstateCancerPanel AR-V7 kits

Circulating tumor cells (CTCs) are important in tumor dissemination. Molecular characterization of CTCs isolated from liquid biopsies can teach us about the biology of tumors cells, new molecular pathways, relevant biomarkers, the mechanisms of cancer progression and even tumor-therapy resistance.…

Gain new insights with CTCs — discover the AdnaTest LungCancer and ProstateCancerPanel AR-V7 kits

Source

0
(0)

Circulating
tumor cells (CTCs) are important in tumor dissemination. Molecular
characterization of CTCs isolated from liquid biopsies can teach us about the
biology of tumors cells, new molecular pathways, relevant biomarkers, the
mechanisms of cancer progression and even tumor-therapy resistance. QIAGEN’s
new AdnaTest LungCancer and ProstateCancerPanel AR-V7 kits can give you added
insights that may help you make your next big discovery!

In this webinar, we present the new AdnaTest LungCancer and
ProstateCancerPanel AR-V7 kits.

The new AdnaTest ProstateCancerPanel AR-V7 detects splice variant AR-V7, an
essential marker for therapy resistance to prostate cancer. This kit uses a
immunomagnetic cell-selection system to enrich circulating tumor cells from
human blood and to detect genes associated with prostate cancer, including
AR-V7, using real-time PCR.

The new AdnaTest LungCancer Kit can be used to explore the molecular
mechanisms of lung cancer through highly specific selection of CTCs in
combination with a sensitive detection of a mix of targets associated with
lung cancer. This kit detects the epithelial-to-mesenchymal transition, an
important marker of cancer-therapy resistance, and specifically selects CTCs against
a high leukocyte background, providing data that is easy to interpret.

Both AdnaTest kits are flexible enough to accommodate detection of
alternative or novel biomarkers. Get easy, fast, highly accurate and reliable
disease-status interpretation using only 5 ml of blood!

0 / 5. 0

Leave a Reply